Candida auris: Killer fungus warning as 'global threat' already detected in UK
A new warning has been issued over the spread of a killer fungus - with cases having already been detected in the UK.
Cases of Candidozyma auris, previously known as candida auris, is spreading in hospitals around the globe and has since caused further alarm after becoming increasingly resistant to medicines that combat it. Following its discovery, the fungus has been associated with deaths with a fatality rate estimated to be one in three.
The World Health Organisation listed C. auris as among the 19 lethal fungi and highlighted its "threat to global public health." A newly reported case found a 34-year-old man developed an infection about three months after he suffered a traumatic brain injury in a car accident. It comes after the NHS warns mouth symptom could be life-shortening disease.
Medical staff at Saqr Hospital in Ras Al-Khaimah said the man was admitted to intensive care with bleeding from his mouth. He also suffered from several cuts and was found to have severe scalp laceration, MailOnline reported.
The man ended up needing three weeks in intensive care and was found to have multiple brain bleeds. He underwent emergency surgery where part of his skull ended up being removed to relieve pressure.
Tests carried out following the surgery revealed he had a C. auris infection. The fungus was first identified in 2009 and it was discovered it could survive on hospital surfaces and the skin for lengthy periods of time.
It is typically resistant to disinfectant and medication and has been found to spread to the blood, brain, spinal cords and bones. The fungus has become more resilient due to the overuse of antifungal agents,
Doctors writing in the Journal of Medical Case Reports said: "The excessive use of antifungal agents in agriculture and healthcare has contributed to the development of antifungal resistance in C. auris. To our knowledge, this is the first case report documenting successful management of a C. auris external ventricular shunt infection without the use of intrathecal antifungal administration."
People who suffer from existing preconditions are particularly considered to be at risk with the fungus being fatal in between an estimated 30 per cent and 60 per cent of patients, reports the Express.
Cases of C. auris have been identified in more than 40 counties across six continents. A UKHSA report, the infection has been "rapidly emerging" across England and has drawn significant concern.
The UKHSA report said: "C. auris represents a growing global health concern, particularly in healthcare settings where it can spread rapidly and resist treatment and some disinfectants. While not yet widespread in England, it is important that we remain aware that C. auris may spread in hospital environments.
"Through effective infection prevention and control measures, rigorous hygiene practices, ongoing monitoring and continued research, its spread can be minimised. C. auris primarily spreads through contact with contaminated surfaces or medical equipment, or via direct contact with individuals who are colonised.
"People can carry the fungus on their skin without developing an infection (called colonisation). However, someone who has C. auris on their skin may become infected if it enters their body, for example through a wound, or if they have had an invasive medical device inserted, for example a catheter or drip."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Powys County Times
27 minutes ago
- Powys County Times
Government partners with Mounjaro maker to tackle obesity
The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity. The move could see patients accessing care at pharmacies or by using online platforms. The £85 million programme from Eli Lilly and the Department for Science, Innovation and Technology (DSIT) has been designed to look at how obese patients can access weight management care more easily. This includes through community services, in pharmacies and online. Using these tools, eligible patients could be treated 'in a matter of months', according to Health Secretary Wes Streeting. Under the agreement, the Government will contribute up to £50 million in UK-wide investment. Meanwhile, Eli Lilly will back the programme with £35 million, and NHS organisations will be able to apply for a share of the funding. Successful applicants can then use the cash to run and assess a pilot to build evidence for efficient obesity care in the UK. Eligible patients could be able to access these innovative services by summer 2026, the Government said. Mr Streeting warned that obesity is one of the leading causes of ill health and costs the health service billions. 'Yet, we now have the science, technology and knowledge to help tackle the obesity epidemic, if we seize this opportunity,' he added. 'This collaboration will help patients living with obesity in a matter of months – through testing better access to weight loss services and treatments. 'In the long-term it will inform how we can better tackle one of the biggest modern day health challenges and, through our Plan for Change, create an NHS that is fit for the future.' Science and Technology Secretary Peter Kyle said new ways of accessing support 'could be transformational for people's quality of life, and for society'. They could free obese people from 'ill-health that holds them back in daily life – while reducing the strain on our NHS', he added. NHS England national medical director Dr Claire Fuller said: 'Obesity is one of the biggest public health challenges we face and costs the NHS billions of pounds every year, so this collaboration between government and industry to drive new ways of supporting people with obesity could make a huge difference. 'The NHS is already developing and rolling out a range of ways to help people to manage their weight and live healthier lives, with patients benefiting from wraparound care from local weight management teams and via online support services, but we are excited by the potential of this collaboration to accelerate efforts to tackle obesity as the NHS moves from treatment to prevention as part of the 10-Year Health Plan.' Professor Rachel Batterham, senior vice president for international medical affairs at Lilly said: 'The launch of this programme marks an important milestone in advancing new models of care for obesity.' Henry Gregg, chief executive of the National Pharmacy Association, welcomed the announcement but warned that funding should cover costs for pharmacies. 'This is a vital step forward in addressing one of the most pressing health challenges facing our country,' he said. 'It's important that any funding made available is sufficient to cover the costs involved for pharmacies to provide wraparound care and support. 'Community pharmacies already support over 1.4 million people every month with weight management services delivered by pharmacists who are highly trained professionals providing expert, accessible care. 'Despite this, the current NHS rollout remains extremely limited, with only a small number of eligible patients receiving support for obesity with weight loss treatments, and it is vital that this changes. 'With the right funding, pharmacies can scale up delivery quickly – ensuring more people get the help they need, when and where they need it.' News of the programme comes after Lilly published the results of a trial assessing a new daily pill for weight loss, which could offer a new and convenient alternative to jabs. People taking orforglipron lost an average of 12.3 kilograms in 72 weeks compared with those not taking the drug. The phased NHS roll-out of Lilly's weight loss jab Mounjaro to patients in England started in June for patients with a body mass index (BMI) over 40 and at least four co-morbidities.
North Wales Chronicle
27 minutes ago
- North Wales Chronicle
Review launched over reports of delayed response to faulty knee replacement part
BBC's File on 4 reported patients were left immobile and addicted to painkillers due to issues with the joint replacement. Some medics have said they first started noticing issues with a part of a knee replacement made by American medical device company Zimmer Biomet around eight years ago. A product recall was not issued until December 2022. A standard total knee replacement has four parts – a femoral component, tibial tray, patellar component and a polyethylene insert. Concerns were raised about the tibial part – also known as 'NexGen Stemmed Option Tibial Component' – as experts found the implant was linked to higher revision rates compared to other models when it was paired with certain other knee replacement components. A recall was led by the Medicines and Healthcare products Regulatory Agency (MHRA) in December 2022 after analysis of National Joint Registry data. Leading knee surgeon Professor Leela Biant said action was not taken quickly enough after problems arose. She told File on 4 that concerns were raised by herself and colleagues around eight years ago – five years before the product recall. 'The issue is their initial reluctance to acknowledge a problem and to not really engage with a process to evaluate these patients until they got to a situation where they had to,' she told the programme. In June 2022, a study was published in the journal Bone & Joint Open which suggested 'there is a fundamental issue with this NexGen implant design'. Patients have told the BBC about the impact on their lives. Debbie Booker, a manager for a company running retirement homes on the south coast, had a knee replacement operation at a local NHS hospital in 2016. Mrs Booker, from Southampton, described how it initially felt like the operation was a success but a year later she was suddenly 'in agony'. As a result of the pain she said she had to take powerful pain killers. 'I was on fentanyl and morphine. I was actually addicted to morphine and it took me a long time to actually come off the morphine because I was addicted,' she said. Medics found the implant had slipped out of place and she needed revision surgery. Another patient, known only as Diana, described how within three years of her left knee replacement surgery she went from being an active retiree to being sofa-bound. 'Every time I stood up I was standing on a broken leg and it was agony,' she told the programme. It also impacted surgeons who used the implant during their operations. One described how they became a surgical 'outlier', with higher revision rates than expected, after using the implant. File on 4 reported the implant had been used on 10,000 patients. Local NHS teams are responsible for reviewing and, where clinically necessary, replacing affected implants. A spokesperson for NHS England said: 'The safety of patients is the absolute priority for the NHS. 'Where issues are identified with any medical device, local NHS teams work swiftly to assess patients and provide replacement treatment where clinically necessary, in accordance with recommendations from the MHRA and device manufacturers. 'NHS England is currently reviewing the case involving Zimmer Biomet NexGen knee implants.' Zimmer Biomet said in a statement: 'Zimmer Biomet is committed to the highest standards of patient safety, quality, and transparency. 'We issued the Field Safety Notice (FSN) proactively and voluntarily, in consultation with the MHRA, after new UK National Joint Registry (NJR) data indicated the Stemmed Option tibial component was not performing as well when used in combination with two specific femoral components (LPS Flex Option and LPS Flex GSF Option) compared to other combinations of components for which the NJR holds data. 'The vast majority of patients had positive outcomes, and we acted swiftly and responsibly by removing the tibial component from the market to prevent future use in those combinations. 'Zimmer Biomet meets all relevant regulatory requirements and maintains a robust post-market surveillance program. 'All our products are approved in accordance with the relevant regulations, and we continuously monitor the performance of our products once they are available to surgeons. 'Patient safety, transparency, and clinical excellence remain our highest priorities.'
South Wales Guardian
27 minutes ago
- South Wales Guardian
Review launched over reports of delayed response to faulty knee replacement part
BBC's File on 4 reported patients were left immobile and addicted to painkillers due to issues with the joint replacement. Some medics have said they first started noticing issues with a part of a knee replacement made by American medical device company Zimmer Biomet around eight years ago. A product recall was not issued until December 2022. A standard total knee replacement has four parts – a femoral component, tibial tray, patellar component and a polyethylene insert. Concerns were raised about the tibial part – also known as 'NexGen Stemmed Option Tibial Component' – as experts found the implant was linked to higher revision rates compared to other models when it was paired with certain other knee replacement components. A recall was led by the Medicines and Healthcare products Regulatory Agency (MHRA) in December 2022 after analysis of National Joint Registry data. Leading knee surgeon Professor Leela Biant said action was not taken quickly enough after problems arose. She told File on 4 that concerns were raised by herself and colleagues around eight years ago – five years before the product recall. 'The issue is their initial reluctance to acknowledge a problem and to not really engage with a process to evaluate these patients until they got to a situation where they had to,' she told the programme. In June 2022, a study was published in the journal Bone & Joint Open which suggested 'there is a fundamental issue with this NexGen implant design'. Patients have told the BBC about the impact on their lives. Debbie Booker, a manager for a company running retirement homes on the south coast, had a knee replacement operation at a local NHS hospital in 2016. Mrs Booker, from Southampton, described how it initially felt like the operation was a success but a year later she was suddenly 'in agony'. As a result of the pain she said she had to take powerful pain killers. 'I was on fentanyl and morphine. I was actually addicted to morphine and it took me a long time to actually come off the morphine because I was addicted,' she said. Medics found the implant had slipped out of place and she needed revision surgery. Another patient, known only as Diana, described how within three years of her left knee replacement surgery she went from being an active retiree to being sofa-bound. 'Every time I stood up I was standing on a broken leg and it was agony,' she told the programme. It also impacted surgeons who used the implant during their operations. One described how they became a surgical 'outlier', with higher revision rates than expected, after using the implant. File on 4 reported the implant had been used on 10,000 patients. Local NHS teams are responsible for reviewing and, where clinically necessary, replacing affected implants. A spokesperson for NHS England said: 'The safety of patients is the absolute priority for the NHS. 'Where issues are identified with any medical device, local NHS teams work swiftly to assess patients and provide replacement treatment where clinically necessary, in accordance with recommendations from the MHRA and device manufacturers. 'NHS England is currently reviewing the case involving Zimmer Biomet NexGen knee implants.' Zimmer Biomet said in a statement: 'Zimmer Biomet is committed to the highest standards of patient safety, quality, and transparency. 'We issued the Field Safety Notice (FSN) proactively and voluntarily, in consultation with the MHRA, after new UK National Joint Registry (NJR) data indicated the Stemmed Option tibial component was not performing as well when used in combination with two specific femoral components (LPS Flex Option and LPS Flex GSF Option) compared to other combinations of components for which the NJR holds data. 'The vast majority of patients had positive outcomes, and we acted swiftly and responsibly by removing the tibial component from the market to prevent future use in those combinations. 'Zimmer Biomet meets all relevant regulatory requirements and maintains a robust post-market surveillance program. 'All our products are approved in accordance with the relevant regulations, and we continuously monitor the performance of our products once they are available to surgeons. 'Patient safety, transparency, and clinical excellence remain our highest priorities.'
